This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Pompe Disease Overview
- Therapeutics Development
- Pipeline Products for Pompe Disease - Overview
- Pipeline Products for Pompe Disease - Comparative Analysis
- Pompe Disease - Therapeutics under Development by Companies
- Pompe Disease - Therapeutics under Investigation by Universities/Institutes
- Pompe Disease Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Pompe Disease - Products under Development by Companies
- Pompe Disease - Products under Investigation by Universities/Institutes
- Pompe Disease - Companies Involved in Therapeutics Development
- Alexion Pharmaceuticals, Inc.
- Amicus Therapeutics, Inc.
- Audentes Therapeutics, Inc.
- BioMarin Pharmaceutical Inc.
- EpiVax, Inc.
- Etubics Corporation
- Genzyme Corporation
- Greenovation Biotech GmbH
- Oxyrane Belgium NV
- Pharming Group N.V.
- RespireRx Pharmaceuticals Inc.
- Sarepta Therapeutics, Inc.
For more information visit http://www.researchandmarkets.com/research/23ftvq/pompe_disease